MB-06322, a fructose-1,6-bisphosphatase inhibitor, effective in rat models of type 2 diabetes June 14, 2006
DPP-IV inhibitor developed at Point Therapeutics shows antidiabetic potential in preclinical studies June 13, 2006
RSS